Stone expulsion time · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Intervention not reported
Impulsivity Q‐sort, Porteus Maze Test (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event1 Pain as assessed by VAS (0 to 10; higher score is worse) · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia1 Spectrophotometer to assess facial redness · Participants with rosacea
1 finding from 1 review
Lesion count ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment: satisfaction with treatment Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light may leads to higher participant global assessment: satisfaction with treatment… compared with no treatment (low certainty).
1 finding from 1 review
Participant global assessment: satisfaction with treatment ‐ axilla Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light may leads to higher participant global assessment: satisfaction with treatment ‐ axilla… compared with no treatment (low certainty).
1 finding from 1 review
Participant global assessment: satisfaction with treatment ‐ groin Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light showed no clear difference in participant global assessment: satisfaction with treatment ‐ groin… compared with no treatment (low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Low
Participant global assessment: satisfaction with treatment ‐ inframammary Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light showed no clear difference in participant global assessment: satisfaction with treatment ‐… compared with no treatment (low certainty).
1 finding from 1 review
RR 3 [0.24, 37.67]
1 study · 2 participants
Low
Dialysis · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in dialysis at end of study compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Remission · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in remission at 6 months compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · adults with renal vasculitis
Pulse cyclophosphamide may leads to higher relapse at the end of compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events ‐ treatment failure · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Serious infections · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Death at final · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in death at final compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review